Nabriva Therapeutics AG Valuation
| NBRVDelisted Stock | USD 1.62 0.01 0.61% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Nabriva Therapeutics secures a last-minute Real Value of $1.41 per share. The latest price of the firm is $1.62. Our model forecasts the value of Nabriva Therapeutics from analyzing the firm fundamentals such as Return On Equity of -2.69, profit margin of (1.48) %, and Current Valuation of 3.29 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Nabriva Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Nabriva Therapeutics is based on 3 months time horizon. Increasing Nabriva Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Nabriva stock is determined by what a typical buyer is willing to pay for full or partial control of Nabriva Therapeutics AG. Since Nabriva Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nabriva Stock. However, Nabriva Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.62 | Real 1.41 | Hype 1.62 | Naive 1.62 |
The intrinsic value of Nabriva Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nabriva Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nabriva Therapeutics AG helps investors to forecast how Nabriva stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nabriva Therapeutics more accurately as focusing exclusively on Nabriva Therapeutics' fundamentals will not take into account other important factors: Nabriva Therapeutics Total Value Analysis
Nabriva Therapeutics AG is now projected to have valuation of 3.29 M with market capitalization of 4.55 M, debt of 5.22 M, and cash on hands of 20.04 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Nabriva Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.29 M | 4.55 M | 5.22 M | 20.04 M |
Nabriva Therapeutics Investor Information
The company has price-to-book ratio of 0.24. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nabriva Therapeutics recorded a loss per share of 19.67. The entity last dividend was issued on the 3rd of December 2020. The firm had 1:25 split on the 16th of September 2022. Based on the key indicators related to Nabriva Therapeutics' liquidity, profitability, solvency, and operating efficiency, Nabriva Therapeutics AG is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Nabriva Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Nabriva Therapeutics has an asset utilization ratio of 112.29 percent. This indicates that the Company is making $1.12 for each dollar of assets. An increasing asset utilization means that Nabriva Therapeutics AG is more efficient with each dollar of assets it utilizes for everyday operations.Nabriva Therapeutics Ownership Allocation
Roughly 90.27 % of Nabriva Therapeutics outstanding shares are held by general public with 0.96 pct. owned by insiders and only 8.77 % by institutional investors.Nabriva Therapeutics Profitability Analysis
The company reported the previous year's revenue of 35.67 M. Net Loss for the year was (57.19 M) with loss before overhead, payroll, taxes, and interest of (10.23 M).About Nabriva Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Nabriva Therapeutics. We calculate exposure to Nabriva Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Nabriva Therapeutics's related companies.Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. Nabriva Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.
Nabriva Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Nabriva Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.7 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |